Drug Type Small molecule drug |
Synonyms BML 258, SK1 I, SK1-I |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC17H27NO2 |
InChIKeyJYEXUQKROPHSEF-SFDDJJRUSA-N |
CAS Registry1072443-89-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Preclinical | United States | 22 Apr 2020 | |
Respiratory Insufficiency | Preclinical | United States | 22 Apr 2020 | |
Colitis, Ulcerative | Preclinical | United States | 19 Feb 2020 | |
Hepatitis, Autoimmune | Preclinical | United States | 19 Feb 2020 | |
Systemic Lupus Erythematosus | Preclinical | United States | 19 Feb 2020 | |
Acute Lymphoblastic Leukemia | Preclinical | United States | 03 Dec 2018 | |
Acute Myeloid Leukemia | Preclinical | United States | 03 Dec 2018 | |
Breast Cancer | Preclinical | United States | 03 Dec 2018 | |
Glioblastoma | Preclinical | United States | 03 Dec 2018 | |
Hematologic Neoplasms | Preclinical | United States | - |